|
|
|
| Clinical distribution and change of drug resistance of Proteus mirabilis causing nosocomial infections in our hospital from 2012 to 2015 |
| YU Boxin1 ZHANG Yajie2 LIU Dan1 LI Qiang3 WANG Jiahe1 |
1.Department of Geriatrics, Shengjing Hospital of China Medical University, Liaoning Province, Shenyang 110004, China;
2.Department of Emergency, Shengjing Hospital of China Medical University, Liaoning Province, Shenyang 110004, China;
3.Department of Laboratory Medicine, Shengjing Hospital of China Medical University, Liaoning Province, Shenyang 110004, China |
|
|
|
|
Abstract Objective To analyze the clinical distribution and drug resistance of Proteus mirabilis causing nosocomial infections in Shengjing Hospital of China Medical University (“our hospital” for short), in order to provide evidence for choosing antibiotics reasonably. Methods The clinical distribution and drug resistance of Proteus mirabilis in hospitalized patients from 1 January 2012 to 31 December 2015 were studied retrospectively. Results A total of 266 strains were isolated. The specimens mainly isolated from urine (57.89%), followed by secretion (9.02%), drainage fluids (7.89%), sputum (7.89%), pus(7.14%) and blood(3.76%). The specimens were mainly isolated from the Department of Urinary Surgery (19.92%), followed by Intensive Care Unit (12.78%) and Department of Rehabilitation (10.53%). The drug resistance rates of Proteus mirabilis to Furantoin, Tetracycline were >90%, to Ticarcillin/Clavulanic Acid, Ertapenem were lowest，both 0. The resistance rate of Proteus mirabilis to Cefazolin increased markedly, from 54.55% to 92.59%, to Ceftazidime and Cefepime decreased sharply, from 33.33%, 36.11% to 3.70% and 7.32%, respectively. Conclusion Proteus mirabilis separation rate from 2012 to 2015 is in a growing trend. This trend reminds that along with the extensive use of antibiotics clinically, the hospital infection rate showes a trend of rising. Proteus mirabilis has different drug resistance to different antimicrobial drugs. It is essential for strengthening the management of antimicrobial abuse and monitoring results of antibiotic resistance.
|
|
|
|
|
|
[1] Gordon KA，Jones RN，SENTRY Participant Groups（Europe，Latin America，North America）. Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America：comparison report to Europe and Latin America：results from the SENTRY Antimicrobial Surveillance Program（2000）[J].Diagn Microbiol Infect Dis，2003，45（4）：295-301.
[2] Farrell DJ，Morrissey I，De Rubeis D，et al. A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection [J]. J Infect，2003， 46（2）：94-100.
[3] Ranjbar-Omid M，Arzanlou M，Amani M，et al. Allicin from garlic inhibits the biofilm formation and urease activity of Proteus mirabilis in vitro [J]. FEMS Microbiol Lett，2015， 362（9）：49.
[4] 石晓路，扈庆华，林一曼，等.致腹泻奇异变形杆菌病原学及其分子特征研究[J].中华流行病学杂志，2014，35（6）：724-728.
[5] Armbruster CE，Hodges SA，Smith SN，et al. Arginine promotes Proteus mirabilis motility and fitness by contributing to conservation of the proton gradient and proton motive force [J]. Microbiologyopen，2014，3（5）：630-641.
[6] 姚金元，杨一鸣，顾蓓青，等.135株奇异变形杆菌的标本分布及耐药性分析[J]．中国消毒学杂志，2016，33（3）：289-290．
[7] 杨承，杨美方，熊晖，等.环介导等温扩增法检测尿液中奇异变形杆菌临床价值[J].中华实用诊断与治疗杂志，2011，25（1）：58-59.
[8] Johansen TE，Cek M，Naber KG，et al. Hospital acquired urinary tract infections in urology departments：pathogens，susceptibility and use of antibiotics. Data from the PEP and PEAP-studies [J]. Int J Antimicrob Agents，2006，28（1）：91-107.
[9] Warren JW，Tenney JH，Hoopes JM，et al. A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters [J]. J Infect Dis，1982，146（6）：719-723.
[10] Liu MC，Kuo KT，Chien HF，et al. New Aspects of RpoE in Uropathogenic Proteus mirabilis [J]. Infect Immun，2015， 83（3）：966-977.
[11] 马巧红，陈群英，何娟妃.132株奇异变形杆菌的临床分布及药敏分析[J].中国微生态学杂志，2012，24（4）：162-164.
[12] 卢雪明，曾翠兰.62株奇异变形杆菌的耐药性分析[J].青岛医药卫生，2010，42（1）：7-9.
[13] Cohen-Nahum K，Saidel-Odes L，Riesenberg K，et al. Urinary tract infections caused by multi-drug resistant Proteus mirabilis：Risk Factors and clinical outcomes [J]. Infection，2010，38（1）：41-46.
[14] 年华，褚云卓，田素飞，等.奇异变形杆菌耐药性变迁10年连续监测分析[J].中国公共卫生，2012，28（8）：1130-1132.
[15] Melo LDR，Patrícia V，Nuno C，et al. Development of a Phage Cocktail to Control Proteus mirabilis Catheter-associated Urinary Tract Infections [J]. Front Microbiol，2016， 7（1024）：1-12.
[16] Kwiecinskapiróg J，Bogiel T，Skowron K，et al. Proteus mirabilis biofilm-Qualitative and quantitative colorimetric methods-based evaluation [J]. Braz J Microbiol，2014， 45（4）：1423-1431.
[17] Endimiani A，Luzzaro F，Brigante G，et al. Proteus mirabilis bloodstream infections：risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases [J]. Antimicrob Agents Chemother，2005，49（7）：2598-2605.
[18] Hernández JR，Martínez-Martínez L，Pascual A，et al. Trends in the susceptibilities of proteus mirabilis isolates to quinolones [J]. J Antimicrob Chemother，2000，45（3）：407-408.
[19] Saito R，Okugawa S，Kumita W，et al. Clinical epidemiology of ciprofloxacin-resistant Proteus mirabilis isolated from urine samples of hospitalised patients [J]. Clin Microbiol Infect，2007，13（12）：1204-1206.
[20] 彭亮，黄瑞娇，肖柯玲，等.2011-2013年奇异变形杆菌临床分离株的耐药性分析[J].热带医学杂志，2014，14（7）：853-855. |
|
|
|
